The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience†
Abstract
UNLABELLED: We took advantage of the reported genotype/phenotype classification to analyze our surgical series of hepatocellular adenoma (HCA). The series without specific known etiologies included 128 cases (116 women). The number of nodules varies from single, <5, and >or=5 in 78, 38, and 12 cases, respectively. The resection was complete in 95 cases. We identified 46 HNF1alpha-inactivated HCAs (44 women), 63 inflammatory HCAs (IHCA, 53 women) of which nine were also beta-catenin-activated, and seven beta-catenin-activated HCAs (all women); six additional cases had no known phenotypic marker and six others could not be phenotypically analyzed. Twenty-three of 128 HCAs showed bleeding. No differences were observed in solitary or multiple tumors in terms of hemorrhagic manifestations between groups. In contrast, differences were observed between the two main groups. Steatosis (tumor), microadenomas (resected specimen), and additional benign nodules were more frequently observed in HNF1alpha-inactivated HCAs (P < 0.01) than in IHCAs. Body mass index > 25, peliosis (tumor), and steatosis in background liver were more frequent in IHCA (P < 0.01). After complete resection, new HCAs in the centimetric range were more frequently found during follow-up (>1 year) in HNF1alpha-inactivated HCA. After incomplete resection (HCA left in nonresected liver), the majority of HCA remained stable in the two main groups and even sometimes regressed. Six patients of 128 developed hepatocellular carcinoma (HCC) (all were beta-catenin-activated, whether inflammatory or not). CONCLUSION: There were noticeable clinical differences between HNF1alpha-inactivated HCA and IHCA; there was no increased risk of bleeding or HCC related to the number of HCAs; beta-catenin-activated HCAs are at higher risk of HCC. As a consequence, we believe that management of HCA needs to be adapted to the phenotype of these tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zucman-Rossi, J., Jeannot, E., Van Nhieu, J. T., Scoazec, J.-Y., Guettier, C., Rebouissou, S., Bacq, Y., Leteurtre, E., Paradis, V., Michalak, S., et al. (2006) · Hepatology · doi:10.1002/hep.21068 · Cited by 760
Self-citationPOSSIBLE ASSOCIATION BETWEEN BENIGN HEPATOMAS AND ORAL CONTRACEPTIVES
BAUM, J. (1973) · The Lancet · doi:10.1016/s0140-6736(73)92594-4 · Cited by 611
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry
Bioulac-Sage, P., Rebouissou, S., Thomas, C., Blanc, J.-F., Saric, J., Sa Cunha, A., Rullier, A., Cubel, G., Couchy, G., Imbeaud, S., et al. (2007) · Hepatology · doi:10.1002/hep.21743 · Cited by 590
Self-citationFrequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
Rebouissou, S., Amessou, M., Couchy, G., Poussin, K., Imbeaud, S., Pilati, C., Izard, T., Balabaud, C., Bioulac-Sage, P., & Zucman-Rossi, J. (2009) · Nature · doi:10.1038/nature07475 · Cited by 477
Self-citationFléjou, J., Barge, J., Menu, Y., Degott, C., Bismuth, H., Potet, F., & Benhamou, J. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90220-3 · Cited by 279
Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma
Rebouissou, S., Bioulac-Sage, P., & Zucman-Rossi, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.10.003 · Cited by 252
Self-citationAndrogens and liver tumors: Fanconi's anemia and non‐Fanconi's conditions
Velazquez, I., & Alter, B. P. (2004) · American Journal of Hematology · doi:10.1002/ajh.20183 · Cited by 237
Bioulac-Sage, P., Rebouissou, S., Sa Cunha, A., Jeannot, E., Lepreux, S., Blanc, J.-F., Blanché, H., le Bail, B., Saric, J., Laurent-Puig, P., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.02.004 · Cited by 199
Self-citationBacq, Y., Jacquemin, E., Balabaud, C., Jeannot, E., Scotto, B., Branchereau, S., Laurent, C., Bourlier, P., Pariente, D., De Muret, A., et al. (2003) · Gastroenterology · doi:10.1016/j.gastro.2003.07.012 · Cited by 184
Self-citationBioulac‐Sage, P., Laumonier, H., Rullier, A., Cubel, G., Laurent, C., Zucman‐Rossi, J., & Balabaud, C. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01849.x · Cited by 158
Self-citation
Cited by
EASL Clinical Practice Guidelines on the management of benign liver tumours
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.001 · Cited by 534
ACG Clinical Guideline: The Diagnosis and Management of Focal Liver Lesions
Marrero, J. A., Ahn, J., & Reddy, R. K. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.213 · Cited by 477
Nault, J.-C., Couchy, G., Balabaud, C., Morcrette, G., Caruso, S., Blanc, J.-F., Bacq, Y., Calderaro, J., Paradis, V., Ramos, J., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.042 · Cited by 401
Self-citationChen, K.-F., Chen, H.-L., Tai, W.-T., Feng, W.-C., Hsu, C.-H., Chen, P.-J., & Cheng, A.-L. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.175786 · Cited by 317
Hepatocellular Benign Tumors—From Molecular Classification to Personalized Clinical Care
Nault, J., Bioulac–Sage, P., & Zucman–Rossi, J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.032 · Cited by 299
Self-citation
Metadata
- Authors
- Bioulac‐Sage, P., Laumonier, H., Couchy, G., Le Bail, B., Sa Cunha, A., Rullier, A., Laurent, C., Blanc, J., Cubel, G., Trillaud, H., Zucman‐Rossi, J., Balabaud, C., & Saric, J.
- Venue
- Hepatology
- Published
- 2009-08
- Volume
- 50
- Issue
- 2
- Pages
- 481-489
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1973650767
- Cited by
- 439
- References
- 15
- FWCI
- 18.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience†. https://app.cochat.ai/papers/10.1002/hep.22995
- The paper
- Bioulac‐Sage, P., Laumonier, H., Couchy, G., Le Bail, B., Sa Cunha, A., Rullier, A., Laurent, C., Blanc, J., Cubel, G., Trillaud, H., Zucman‐Rossi, J., Balabaud, C., & Saric, J. (2009). Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience†. Hepatology. https://doi.org/10.1002/hep.22995
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.